DHEA treatment of Alzheimer's disease: A randomized, double-blind, placebo-controlled study

Neurology

Volumn 60, Issue 7, 2003, Pages 1071-1076

  Wolkowitz, O M ^a,i   Kramer, J H ^a   Reus, V I ^a   Costa, M M ^a   Yaffe, K ^a   Walton, P ^a   Raskind, M ^b   Peskind, E ^b   Newhouse, P ^c   Sack, D ^d   De Souza, E ^e,f   Sadowsky, C ^g   Roberts, E ^h   Schaerf, F ^j   Strauss, A ^j   Charles, L ^k   Wecker, N ^l   Segal, M ^l  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^d Inst for Psychopharmacology Res   (United States)

^e NEUROCRINE BIOSCIENCES INC   (United States)

^f SANOFI   (France)

^g Premiere Research Institute   (United States)

^h CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

ⁱ Box F 0984 ^*  (United States)

^j Clinical Studies Ltd   (United States)

^k S New Jersey Medical Institute   (United States)

^l UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; PRASTERONE;

AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; TREATMENT OUTCOME;

EID: 0037426387     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.WNL.0000052994.54660.58     Document Type: Article

References (29)

1. Baulieu EE. Neurosteroids: of the nervous system, by the nervous system, for the nervous system. Recent Prog Horm Res 1997;52:1-32.
2. Leblhuber F, Neubauer C, Peichl M, et al. Age and sex differences of dehydroepiandrosterone sulfate (DHEAS) and cortisol (CRT) plasma levels in normal controls and Alzheimer's disease (AD). Psychopharmacology 1993;111:23-26.
3. Ferrari E, Arcaini A, Gornati R, et al. Pineal and pituitary- adrenocortical function in physiological aging and in senile dementia. Exp Gerontol 2000;35:1239-1250.
4. Wolkowitz OM, Kroboth P, Reus VI, Fabian TJ. Dehydroepiandrosterone in aging and mental health. In: Morrison MF, ed. Hormones, Gender and the aging brain: the endocrine basis of geriatric psychiatry. Cambridge: Cambridge University Press, 2000;144-167.
5. Magri F, Terenzi F, Ricciardi T, et al. Association between changes in adrenal secretion and cerebral morphometric correlates in normal aging and senile dementia. Dement Geriatr Cogn Disord 2000;11:90-99.
6. Murialdo G, Nobili F, Rollero A, et al. Hippocampal perfusion and pituitary-adrenal axis in Alzheimer's disease. Neuropsychobiology 2000;42:51-57.
7. Bologa L, Sharma J, Roberts E. Dehydroepiandrosterone and its sulfate derivative reduce neuronal death and enhance astrocytic differentiation in brain cell cultures. J Neurosci Res 1987;17:225-234.
8. Kimonides VG, Khatibi NH, Svendsen CN, Sofroniew MV, Herbert J. Dehydroepiandrosterone (DHEA) and DHEA-sulfate (DHEAS) protect hippocampal neurons against excitatory amino acid-induced neurotoxicity. Proc Natl Acad Sci USA 1998;95:1852-1857.
9. Bastianetto S, Ramassamy C, Poirier J, Quirion R. Dehydroepiandrosterone (DHEA) protects hippocampal cells from oxidative stress-induced damage. Brain Res Mol Brain Res 1999;66:35-41.
10. Svec F, Porter JR. The actions of exogenous dehydroepiandrosterone in experimental animals and humans. Proc Soc Exp Biol Med 1998;218:174-191.
11. Flood JF, Roberts E. Dehydroepiandrosterone sulfate improves memory in aging mice. Brain Res 1988;448:178-181.
12. Wolkowitz OM, Brizendine L, Reus VI. The Role of dehydroepiandrosterone (DHEA) in psychiatry. Psychiatr Ann 2000;30:123-128.
13. Wolkowitz OM, Reus VI. Neuropsychiatric effects of dehydroepiandrosterone (DHEA). In: Kalimi M, Regelson W, eds. Dehydroepiandrosterone (DHEA): biochemical, physiological and clinical aspects. Berlin: Walter De Gruyter, 2000;271-298.
14. Huppert FA, Van Niekerk JK. Dehydroepiandrosterone (DHEA) supplementation for cognitive function (Cochrane Review). The Cochrane Library. Oxford: Update Software, 2001.
15. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.
16. Rosen WG, Terry RD, Fuld PA, Katzman R, Peck A. Pathological verification of ischemic score in differentiation of dementias. Ann Neurol 1980;7:486-488.
17. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state." A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
18. Malloy PF, Cummings JL, Coffey CE, et al. Cognitive screening instruments in neuropsychiatry: a report of the Committee on Research of the American Neuropsychiatric Association. J Neuropsychiatry Clin Neurosci 1997;9:189-197.
19. Wolkowitz OM, Reus VI, Keebler A, et al. Double-blind treatment of major depression with dehydroepiandrosterone (DHEA). Am J Psychiatry 1999;156:646-649.
20. Bloch M, Schmidt PJ, Danaceau MA, Adams LF, Rubinow DR. Dehydroepiandrosterone treatment of mid-life dysthymia. Biol Psychiatry 1999;45:1533-1541.
21. Rosen WG, Mohs R, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984;141:1356-1364.
22. Schneider LS, Olin JT, Doody RS, et al. Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997;11:S22-S32.
23. Alexopoulos GS, Abrams RC, Young RC, Shamoian CA. Cornell scale for depression in dementia. Biol Psychiatry 1988;23:271-284.
24. Nafziger AN, Bowlin SJ, Jenkins PL, Pearson TA. Longitudinal changes in dehydroepiandrosterone concentrations in men and women. J Lab Clin Med 1998;131:316-323.
25. US Department of Health Education and Welfare. Coding symbols for thesaurus of adverse reaction terms (COSTART). Rockville, MD: US Food and Drug Administration, Center for Drug Evaluation and Research, 1995.
26. Dukoff R, Molchan S, Putnam K, Lai J, Sunderland T. Dehydroepiandrosterone administration in demented patients and non-demented elderly volunteers. Biol Psychiatry 1998;43:55S. Abstract.
27. Azuma T, Nagai Y, Saito T, Funauchi M, Matsubara T, Sakoda S. The effect of dehydroepiandrosterone sulfate administration to patients with multi-infarct dementia. J Neurol Sci 1999;162:69-73.
28. van Vollenhoven RF. Dehydroepiandrosterone. Uses and abuses. In: Kelley WN, Harris Jr ED, Ruddy S, Sledge CB, eds. Textbook of rheumatology. Philadelphia: WB Saunders, 1997;1-25.
29. Yaffe K, Sawaya G, Lieberburg I, Grady D. Estrogen therapy in postmenopausal women: effects on cognitive function and dementia. JAMA 1998;279:688-695.